SAT0166 GOLIMUMAB AS FIRST, SECOND OR AT LEAST THIRD BIOLOGIC AGENT IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA), PSORIATIC ARTHRITIS (PSA) OR ANKYLOSING SPONDYLITIS (AS) – POST HOC ANALYSIS OF A NON-INTERVENTIONAL STUDY IN GERMANY
Sign Up to like & getrecommendations! Published in 2019 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2019-eular.3245
Abstract: Background Golimumab (GLM) has demonstrated efficacy in RA, PsA, and AS in several randomized clinical trials with biologic-naïve patients. Data from real world practice comparing biologic naïve and experienced patients are lacking. Objectives The aim… read more here.
Keywords: line; basdai; first second; least third ... See more keywords